Sun Pharma's Unloxcyt Delivers 50% Response Rate at ASCO

Health

Sock JohnsonSock Johnson

Sun Pharma's Unloxcyt Delivers 50% Response Rate at ASCO

Listen up, folks! Sun Pharma just announced that their skin cancer champ, Unloxcyt, is strutting its stuff at the ASCO Annual Meeting! With a 50% response rate and 27% of patients going full-on rockstar, this therapy is ready to deliver a knockout punch against skin cancer! After 31 months, it’s still showing off its durability and safety like a true heavyweight!